Dietary Docosahexaenoic Acid-Rich Supplementation Decreases Neurotoxic Lipid Mediators in Participants with Type 2 Diabetes and Neuropathic Pain
Nutrients · 2024
DOI: 10.3390/nu16234025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Alfonso M Durán und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, U…. Hauptthemen laut MEDLINE: Docosahexaenoic Acids, Diabetes Mellitus, Type 2, Dietary Supplements, Diabetic Neuropathies. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIH.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background/Objectives: There is increasing evidence linking circulating neurotoxic lipids to the progression of chronic neuroinflammatory diseases in the peripheral and central nervous systems. Strategies to modify lipid profiles, such as docosahexaenoic acid (DHA)-rich supplementation, may aid in managing conditions like painful diabetic neuropathy (pDN). In a previous study, we demonstrated that three months of DHA supplementation significantly altered the metabolomic profile of patients with painful diabetic neuropathy (pDN), resulting in symptom improvement. This study investigates whether DHA-rich supplementation reduces neurotoxic lipid mediators associated with pDN in individuals with type 2 diabetes mellitus (T2DM).
Methods
Forty individuals with type 2 diabetes participated in the “En Balance-PLUS” study, attending weekly lifestyle and nutrition education sessions while receiving daily supplementation of 1000 mg DHA and 200 mg EPA. Pain levels were assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ) at baseline and after three months. Blood serum samples collected at these time points underwent untargeted lipidomic analyses, with ELISA used to evaluate biomarkers of necrosis (MLKL), autophagy (ATG5), and lipid chaperone protein (FABP5).
Results
Untargeted lipidomic analysis revealed that several neurotoxic-associated lipids significantly decreased after DHA-rich supplementation. Also, circulating levels of MLKL were reduced, while protein levels of ATG5 and FABP5 significantly increased.
Conclusions
The reduction of circulating neurotoxic lipids and increase in neuroprotective lipids following DHA-rich supplementation are consistent with the reported roles of omega-3 polyunsaturated fatty acids (PUFAs) in reducing adverse symptoms associated with neuroinflammatory diseases and painful neuropathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
ORCID-Profile: Marino De León
Förderung
- NIH HHS
- NIH
Zitieren
APA
Durán, A. M., Zamora, F., & De León, M. (2024). Dietary Docosahexaenoic Acid-Rich Supplementation Decreases Neurotoxic Lipid Mediators in Participants with Type 2 Diabetes and Neuropathic Pain. Nutrients. https://doi.org/10.3390/nu16234025
Vancouver
Durán AM, Zamora F, De León M. Dietary Docosahexaenoic Acid-Rich Supplementation Decreases Neurotoxic Lipid Mediators in Participants with Type 2 Diabetes and Neuropathic Pain. Nutrients. 2024. doi:10.3390/nu16234025
BibTeX
@article{Durn2024,
author = {Durán, Alfonso M and Zamora, Francis and De León, Marino},
title = {Dietary Docosahexaenoic Acid-Rich Supplementation Decreases Neurotoxic Lipid Mediators in Participants with Type 2 Diabetes and Neuropathic Pain},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16234025}
}
EUVIMED